Pu Q, Zhuang D, Thakran S, Hassid A. Mechanisms related to NO-induced motility in differentiated rat aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 300: H101-H108, 2011. First published October 29, 2010 doi:10.1152/ajpheart.00342.2010 is thought to play an important role as an inhibitor of vascular cell proliferation, motility, and neointima formation. This effect is mediated, in part, via the upregulation of protein tyrosine phosphatase (PTP)1B. Conversely, studies have reported that in presumably hyperinsulinemic mice fed a high-fat diet, NO enhances vascular remodeling, whereas a deficit of NO attenuates vascular remodeling. We have reported that in differentiated cultured smooth muscle cells treated with insulin, NO induces a motogenic effect that is dependent on Src homology-2 domain PTP 2 (SHP2) upregulation. In the present study, we describe novel mechanisms relevant to the motogenic effect of NO. Treatment of cultured cells with the selective angiontensin type 1 receptor antagonist losartan, but not with the selective angiotensin type 2 receptor antagonist PD-123319, blocked the comotogenic capacity of NO and insulin. Insulin and NO increased the secretion of ANG II into the culture media by 2-and 2.5-fold (P Ͻ 0.05), respectively, whereas treatment of cells with ANG II uncovered the motogenic effect of NO (1.4-fold above control, P Ͻ 0.05) and decreased the levels of PTP1B to 45% of control (P Ͻ 0.05). Suppression of PTP1B function was sufficient to uncover the motogenic effect of NO. The capacity of insulin to suppress PTP1B activity was blocked by losartan, implicating ANG II function in mediating this effect. Both insulin and ANG II induced the upregulation of phosphatidyl inositol 3-kinase (PI3K)-␦ by two-to threefold (P Ͻ 0.05), and this effect was both necessary and sufficient to uncover NO-induced motogenesis. Finally, suppression of PTP1B function potentiated, whereas overexpression of PTP1B inhibited, SHP2-induced motogenesis. These results support the hypothesis that the comotogenic effect of insulin and NO occurs via an ANG II-mediated effect involving the suppression of PTP1B and upregulation of PI3K-␦ and SHP2. nitric oxide; vascular smooth muscle; angiotensin II; protein tyrosine phosphatases NITRIC OXIDE (NO) is generally thought to attenuate vascular remodeling, and numerous studies have reported that it decreases neointima formation and atherosclerosis in models of vascular injury. In vivo, inducible NO synthase (iNOS) levels have been reported to be increased in medial cells, almost immediately after vascular injury, and subsequently in neointimal cells (12, 34) . Inducible NO levels are also increased in diabetes. Several groups, including ours, have reported that NO donors decrease aortic smooth muscle cell motility and proliferation in culture (11, 24, 26) . Moreover, many in vivo studies have shown that exogenous or endogenous NO attenuates neointima formation induced by vascular injury, consistent with the overall inhibition of vascular smooth muscle cell motility and proliferation in models of vascular injury (29) .
NITRIC OXIDE (NO) is generally thought to attenuate vascular remodeling, and numerous studies have reported that it decreases neointima formation and atherosclerosis in models of vascular injury. In vivo, inducible NO synthase (iNOS) levels have been reported to be increased in medial cells, almost immediately after vascular injury, and subsequently in neointimal cells (12, 34) . Inducible NO levels are also increased in diabetes. Several groups, including ours, have reported that NO donors decrease aortic smooth muscle cell motility and proliferation in culture (11, 24, 26) . Moreover, many in vivo studies have shown that exogenous or endogenous NO attenuates neointima formation induced by vascular injury, consistent with the overall inhibition of vascular smooth muscle cell motility and proliferation in models of vascular injury (29) .
In contrast to the aforementioned studies, we (1, 2) have found that NO stimulates motility in highly differentiated rat aortic smooth muscle cell cultures chronically treated with insulin, via a mechanism involving Src homology-2 domain protein tyrosine phosphatase (SHP2). Moreover, we (8) have reported that chronic insulin treatment abrogates the antimotogenic capacity of NO in cells stimulated with PDGF, by suppressing the function of protein tyrosine phosphatase (PTP)1B. Intriguingly, several in vivo studies have also reported data that challenge the concept that NO is always inhibitory. Thus, iNOS enhances the formation of atherosclerotic lesions in presumably hyperinsulinemic apolipoprotein E (ApoE) knockout mice fed a high-fat diet (7, 17) . Overexpression of endothelial NOS also enhances atherosclerosis in ApoE knockout mice fed a high-fat diet (22) but has the opposite effect in ApoE mice fed regular chow (30) . Hyperinsulinemia also has major deleterious vascular effects in humans. Thus, after angioplasty, restenosis occurs at an increased rate in humans manifesting insulin resistance (16) . Moreover, plasma insulin levels in the United States population have reportedly increased by ϳ35% during the last decade (19) .
Chronic insulin treatment has the capacity to increase intracellular ANG II levels in cultured rat aortic smooth muscle cells (28) , whereas treatment with ANG II increases phosphatidylinositol 3-kinase (PI3K) activity levels (25) . A recent study (15) has reported that treatment of rats with ANG II induces the upregulation of the ␦-isoform of PI3K. Moreover, we (8) have found that inhibition of PI3K function blocks the motogenic effect of NO in insulin-treated cells. On the basis of these findings, we tested the hypothesis that the motogenic effect of NO in insulin-treated cells is mediated by the suppression of PTP1B activity via a signaling pathway involving ANG II, PI3K-␦ and SHP2.
MATERIALS AND METHODS

Materials.
Adult male Sprague-Dawley rats were purchased from Charles River Laboratories (Wilmington, MA). Primaria tissue culture plates were from Falcon/Becton Dickinson (Oxnard, CA). Suspension MEM for suspension culture was from Invitrogen (Carlsbad, CA), and DMEM-Ham's F-12 (1:1) was from Cellgro Mediatech (Herndon, VA). FBS was from Atlanta Biologicals (Lawrenceville, GA). Porcine pancreatic elastase and clostridium histolyticum collagenase were from Worthington Biochemical (Lakewood, NJ). Soybean trypsin inhibitor, BSA (fraction V), bovine pancreatic insulin, protease inhibitor cocktail, isotype control mouse IgG2a, p-nitrophenyl phosphate, acetonitrile, trifluoroacetic acid, losartan, and PD-123319 were from Sigma (St. Louis, MO). Serine/threonine phosphatase inhibitor cocktail and monoclonal antibody against PTP1B (used for Western blot analysis) were from Calbiochem (La Jolla, CA). Monoclonal antibody against PTP1B (used for immunoprecipitation) was from BD Bio-sciences (San Jose, CA). Rabbit anti-ANG II type 1 receptor (AT1R), rabbit anti-ANG II type 2 receptor (AT 2R), and antibodies against PI3K p110-␦ were from Santa Cruz Biotechnology (Santa Cruz, CA). Protein G-Sepharose beads were from GE Healthcare Biosciences AB (Piscataway, NJ). Strata-X 30 mg/3 ml extraction tubes (C18) were from Phenomenex (Torrance, CA). The ANG II enzyme immunoassay kit was from Cayman Chemical (Ann Arbor, MI). Adenovirus expressing iNOS was kindly donated by Dr. Timothy Billiar (University of Pittsburgh, Pittsburgh, PA). Plasmids containing hemagglutinin (HA)-tagged wild-type human sequence PTP1B (pJ3H-PTP435) and dominant negative, catalytically inactive PTP1B (pJ3H-PTP435-C215S, dnPTP1B) were kindly donated by Dr. Jonathan Chernoff (Fox Chase Cancer Institute). Plasmids with a sequence expressing small interfering (si) RNA against rat PI3K-␦ were from Integrated DNA Technologies (Coralville, IA). Plasmids with a sequence expressing siRNA against rat PTP1B and plasmid with a sequence expressing a nontargeting siRNA control were from Ambion (Austin, TX). cDNA of mouse PI3K p110-␦ was obtained from the American Type Culture Collection.
Preparation and expression of adenoviral vectors. Replicationdeficient (E1-deleted) recombinant type 5 adenovirus expressing enhanced green fluorescent protein (EGFP), lac Z, human sequence wild-type PTP1B, dominant negative PTP1B (C215S-PTP1B), or SHP2 were prepared as previously described (5, 8) . Adenovirus expressing mouse PI3K-␦ was prepared as follows: a KpnI restriction site together with double HA epitopes in tandem at the NH 2-terminus and a XbaI restriction site at the COOH-terminus were introduced by PCR into plasmid pEN_PISK110d containing mouse PI3K-␦ cDNA. The PCR product was subcloned into the adenovirus pShuttle vector by directional ligation. The recombinant plasmid integrity was confirmed by DNA sequencing. Recombinant adenovirus expressing PI3K-␦ was obtained by cotransfecting linearized recombinant pShuttle and adenoviral backbone DNA (obtained from the University of Iowa vector core) in human embryonic kidney (HEK)-293 cells, and the virus was purified using an Adeno-X kit (Clontech) according to the manufacturer's instructions.
Adenoviruses expressing siRNA against rat PTP1B or the PI3K adapter protein p110-␦ were prepared using the pSilencer 1.0 CMV kit from Ambion. Hairpin DNA inserts (from IDT or Dharmacon) were first cloned into the Shuttle vector using XhoI/SpeI sites. After PacI restriction for both shuttle and backbone, constructs were cotransfected into HEK-293 cells. The sequences of siRNA against the rat PI3K adapter protein p110-␦ were designed as follows: DNA duplex 1, sense 5=-TCGAGTCATCAACTCACAGATCAGTTCAAGAGACTGATCT-GTGAGTTGATGAGCA-3= and antisense 5=-CTAGTGCTCATCAACT-CACAGATCAGTCTCTTGAACTGATCTGTGAGTTGATGAC-3=; and DNA duplex 2, sense 5=-TCGAGTGAATGCGGATGAAAGGATT-TCAAGAGAATCCTTTCATCCGCATTCACCA-3= and antisense 5=-CTAGTGGTGAATGCGGATGAAAGGATTCTCTTGAAATCCTTT-CATCCGCATTCAC-3=. Sequences of siRNA against rat PTP1B were designed as follows: DNA duplex 1: sense DNA, 5=-TCGAGAGAT-GGTCTTCGATGACACTTCAAGAGAGTGTCATCGAAGACCA-TCTCTA-3=, and antisense DNA, 5=-CTAGTAGAGATGGTCTTCGAT-GACACTCTCTTGAAGTGTCATCGAAGACCATCTC-3=; and DNA duplex 2: sense DNA, 5=-TCGAGGGAGAAGGAATTCGAGCAGT-TCAAGAGACTGCTCGAATTCCTTCTCCATA-3=, and antisense DNA, 5=-CTAGTATGGAGAAGGAATTCGAGCAGTCTCTTGAACTG-CTCGAATTCCTTCTCCC-3=. Two adenovirus constructs, containing either DNA duplex 1 or 2 against PTP1B or the PI3K adapter protein p110-␦ were premixed [1:1 (vol:vol)] before being used for cell infection. It should also be noted that we have previously found that treatment with adenovirus at the multiplicity of infection used in the present study does not induce cytotoxicity, as determined by the lack of trypan blue staining (data not shown).
Cell culture. Smooth muscle cells were obtained from the thoracic aortas of adult Sprague-Dawley rats (100 -120 g) and cultured in a manner that minimizes cellular dedifferentiation, as we have previously reported (8) . All experiments in this study were performed using primary and confluent cultures that were cultured in serum-free medium for 24 Measurement of cell motility. Cell motility was measured via a monolayer wounding assay involving the migration of cells into the breach, as previously described (4) . All experiments were done in the presence of hydroxyurea to prevent cell proliferation, as previously described (4). The motility index was expressed as the distance migrated in 24 h.
Performance of Western blot analysis. To determine PTP1B, PI3K p110-␦, iNOS, SHP2, AT1R, or AT2R protein levels by direct Western blot analysis, cells were subjected to lysis using the following buffer: 188 mM Tris·HCl, 1 mM EDTA, 15% glycerol, and 1% SDS (pH 6.8) further supplemented with 1 mM sodium vanadate, 0.25 mM PMSF, 0.2 M aprotinin, 5.25 M leupeptin, 9 M bestatin, 3.75 M pepstatin A, and 3.5 M E-64. Lysates were subjected to Western blot analysis using the relevant antibodies. Band densities were measured using NIH Image software.
Measurement of PTP1B activity. PTP1B activity was measured as previously described (38) . Briefly, aortic smooth muscle cells were subjected to lysis using ice-cold HEPES buffer of the following composition: 50 mM HEPES, 150 mM NaCl, 2.5 mM EDTA, and 1% Triton X-100 supplemented with protease inhibitor cocktail (0.5 mM PMSF, 0.4 M aprotinin, 10.5 M leupeptin, 18 M bestatin, 7.5 M pepstatin A, and 7 M E-64) and serine/threonine phosphatase inhibitor cocktail (25 M p-bromotetramisole oxalate, 5 M cantharidin, and 5 nM microcystin). PTP1B was immunoprecipitated using anti-PTP1B for 3 h at 4°C, followed by an incubation of immunocomplexes with protein G-Sepharose 4 Fast Flow and beads (50%) for 2 h at 4°C, followed by rinsing twice with ice-cold HEPES buffer (25 mM HEPES, 50 mM NaCl, 2.5 mM EDTA, 10 mM DTT, and 5 mM ␤-mercaptoethanol; pH 7.2). To measure enzyme activity, immunoprecipitated PTP1B was incubated with 10 mM p-nitrophenyl phosphate as a substrate at 37°C. The levels of p-nitrophenol by enzymatic hydrolysis generated by enzymatic reaction were measured via the increase of absorbance at 405 nm.
ELISA for secreted ANG II. Culture media were collected, and ANG II was partially purified by extraction through Strata-X 30 mg/3 ml extraction tubes (C18) preconditioned with methanol followed by water. Media samples mixed with phosphoric acid [50:1 (vol/vol)] were passed through the tubes, washed with 10% acetonitrile in 0.1% trifluoroacetic acid, eluted with acetonitrile-water [80:20 (vol/vol)], evaporated to dryness by vacuum centrifuge, and reconstituted with assay buffer. ANG II was quantitated by ELISA. The concentration of ANG II was calculated from the standard absorbance curve for ANG II. The cross-reactivity characteristics of this assay were as follows: ANG II, 100% ; ANG I, 4%; ANG III, 36%; ANG-(3-8), 33% ; and ANG-(1-7), Ͻ0.01%. The threshold sensitivity of the assay was indicated to be 1 pg/ml by the manufacturer.
Statistical analysis. Results are expressed as means Ϯ SE and were analyzed using two-way ANOVA followed by Fisher's least-significant-difference test or Student's unpaired t-test. P values of Ͻ0.05 were considered statistically significant.
RESULTS
Comotogenic effect of exogenous and endogenous NO.
We (8) have reported that exogenous NO has the capacity to induce motogenesis in insulin-treated cells. As shown in Fig. 1 , treatment with insulin and diethylenetriamine (DETA)-NO, but not either one of them alone, significantly increased cell motility. Moreover, we found that insulin alone failed to induce a significant increase of NO generation, as measured by nitrite/ nitrate accumulation in culture media, a finding that is concordant with the lack of insulin-induced cell motility (data not shown). It should also be noted that concentrations of the NO donor DETA-NO similar to the one used in the present study have been reported to generate NO levels estimated to be ϳ500 nM, well within the range of NO levels thought to occur in vivo, at least under conditions of upregulated NOS (3). Next, we tested the hypothesis that endogenous iNOS, generated via the overexpression of iNOS, would mimic the effect of exogenous NO. As shown in the Supplemental Material (Supplemental Fig. I ), 1 treatment of cells with adenovirus expressing iNOS plus insulin but not with control virus expressing lac Z plus insulin enhanced motogenesis. Moreover, iNOS adenovirus was ineffective in cells not treated with insulin. It should be noted that we verified iNOS expression via Western blot analysis (data not shown). These results indicate that endogenous NO mimics the effect of the exogenous NO donor DETA-NO.
Motogenic effect of NO requires ANG II function. We next tested the hypothesis that the motogenic effect of NO in insulin-treated cells requires ANG II function via AT 1 R. As shown in Fig. 1 , treatment with the AT 1 R-selective antagonist losartan or the AT 2 R-selective antagonist PD-123319 had no effect on basal motility, in either the presence or absence of insulin. However, losartan blocked the comotogenic effect of insulin/DETA-NO, whereas PD-123319 had no significant effect. Saralasin, a nonselective ANG II antagonist, also blocked the comotogenic effect of insulin/DETA-NO (data not shown). Separately, we verified, via Western blot analysis, that cells did not express significant levels of AT 2 R (results not shown), consistent with the lack of effect of the AT 2 R antagonist. These results are consistent with the hypothesis that the comotogenic effect of insulin/DETA-NO requires ANG II activity and that this activity is mediated via AT 1 R.
Both insulin and NO increase the secretion of ANG II levels.
Previous studies (14, 28) have reported that insulin has the capacity to increase the levels of angiotensinogen as well as ANG II in cultured vascular smooth muscle cells. However, the effect of NO on ANG II levels in vascular smooth muscle does not appear to have been investigated, prompting us to determine whether NO could increase ANG II levels in cultured primary aortic smooth muscle cells. DETA-NO had a modest but significant effect on secreted ANG II levels as measured in the culture media (control: 0.68 Ϯ 0.03 pg/ml and DETA-NO: 0.93 Ϯ 0.02, P Ͻ 0.05). Treatment with insulin significantly increased ANG II secretion (to 1.21 Ϯ 0.04 pg/ml, P Ͻ 0.05), confirming previous findings. Combined treatment with insulin and NO induced a marked increase of about threefold in ANG II levels (to 1.92 Ϯ 0.1 pg/ml, P Ͻ 005), consistent with the potential involvement of ANG II in NO-induced cell motility in insulin-treated cells. We also attempted to determine intracellular ANG II levels, but measured values were below the threshold sensitivity of the assay.
Treatment with ANG II uncovers the motogenic effect of NO. The experiments shown in Fig. 1 indicate that ANG II function is required for expression of the comotogenic effect of insulin and NO. We were therefore prompted to determine whether increased ANG II levels are sufficient to uncover NO-induced cell motility. To this end, we treated cells without or with NO in the absence or presence of ANG II. As shown in Fig. 2 , ANG II alone had no effect on motility. However, in NO-treated cells, ANG II increased cell motility in concentration-dependent manner, although the maximal effect induced by ANG II was not as large as the comotogenic effect of insulin.
Insulin induces upregulation of AT 1 R. Previous studies (10, 20, 21) have reported that insulin treatment induces the upregulation of AT 1 R, in addition to an elevation of ANG II levels, as verified above. To verify the increase of AT 1 R in primary cultures, we treated cells with increasing concentrations of insulin. Insulin induced upregulation of AT 1 R in a concentration-dependent (Supplemental Fig. II ) and time-dependent (not shown) manner.
NO increased PTP1B activity but not PTP1B protein levels. We have previously reported that treatment of cultured aortic smooth muscle cells with NO increases the levels of PTP1B 1 Supplemental Material for this article is available at the American Journal of Physiology-Heart and Circulatory Physiology website. activity; it is interesting to note that PTP1B protein levels remained unchanged in NO-treated cells, indicating an increase in the enzyme-specific activity of PTP1B (see Fig. 6 ).
Both insulin and ANG II reduce PTP1B protein levels. We (38) have previously reported that insulin treatment suppresses the increase of PTP1B protein levels induced by PDGF. Here, we tested the hypothesis that insulin decreases basal PTP1B levels in a concentration-dependent manner. Moreover, we hypothesized that if ANG II is a mediator of the effect of insulin, then ANG II should be able to mimic the effect of insulin. Indeed, as shown in Fig. 3 , insulin induced a concentration-dependent decrease of PTP1B levels and ANG II mimicked the effect of insulin. [It should also be noted that NO had no significant effect on PTP1B protein levels (data not shown).]
Insulin suppresses NO-induced PTP1B activation, whereas an AT 1 R antagonist rescues cells from insulin-induced effect. We (13) have previously reported that NO increases PTP1B activity, and in the present study, we verified that DETA-NO increased PTP1B activity levels in a concentration-dependent manner (data not shown). We (23, 38) have also reported that the capacity of PDGF to increase PTP1B activity is suppressed by chronic treatment with insulin. On the basis of these findings and the aforementioned data, we were prompted to test the hypothesis that the increase of PTP1B activity induced by NO would be suppressed by insulin via an ANg II-mediated mechanism. As shown in Fig. 4 , DETA-NO increased PTP1B activity levels, and this effect was significantly reduced by treatment with insulin; moreover, treatment with losartan rescued cells from the inhibitory effect of insulin.
Decrease of PTP1B levels or function is sufficient to uncover the motogenic effect of NO. To test the hypothesis that PTP1B suppression would be sufficient to uncover the motogenic effect of NO, we treated cells with DETA-NO in the presence or absence of siRNA directed against PTP1B or in the presence or absence of dominant negative PTP1B (C215S-PTP1B). As shown in Fig. 5 , treatment with adenovirus expressing siRNA directed against PTP1B or treatment with dominant negative PTP1B, but not adenovirus expressing control siRNA or control virus (Ad.lac Z), uncovered the motogenic effect of the NO donor. These results are consistent with the hypothesis that suppression of PTP1B function is sufficient to uncover the motogenic effect of NO.
Role of PI3K-␦ as a mediator of NO-induced motogenesis. Several studies (15, 25, 27, 33) have reported an important role of PI3K in mediating the actions of insulin as well as ANG II. We (38) have reported that interference with PI3K function blocks the comotogenic effect of NO and PDGF in insulintreated cells and that insulin treatment induces the upregulation of the PI3K ␦-isoform, consistent with data from another laboratory (27) .
On the basis of these findings, we were prompted to determine the effect of insulin or ANG II treatment on PI3K-␦ levels in cultured differentiated aortic smooth muscle cells. As shown in Fig. 6 , both insulin and ANG II induced a significant increase of PI3K-␦ levels in a concentration-dependent manner, thus identifying PI3K-␦ as a potential mediator of the motogenic effect of NO, downstream of insulin and ANG II. Next, we tested the hypothesis that PI3K-␦ function is necessary for expression of the motogenic effect of NO. As shown in Fig. 7 , we verified that treatment with siRNA directed against PI3K-␦ significantly reduced PI3K levels; moreover, treatment with siRNA directed against PI3K-␦ but not with control siRNA blocked the capacity of NO-induced motogenesis in insulin-treated cells. These results are consistent with the hypothesis that PI3K-␦ function is necessary for expression of the comotogenic effect of NO.
We next tested the hypothesis that increased PI3K-␦ activity is sufficient to uncover the motogenic effect of NO. To this end, we treated cells with adenovirus expressing PI3K-␦. As shown in Fig. 8 , overexpression of PI3K-␦ alone had no significant effect on motility, whereas the enzyme uncovered the motogenic effect of DETA-NO, similar to that of DETA-NO in insulin-treated cells. Expression of an unrelated control virus (Ad.EGFP) had no effect on either basal motility or on motility in cells treated with DETA-NO alone or DETA-NO plus insulin.
Treatment with insulin uncovers SHP2-mediated cell motility via a mechanism involving the suppression of PTP1B function. We (8) have previously reported that NO induces increased SHP2 levels and that the comotogenic effect of NO in insulin-treated cells is mediated via SHP2, as documented by the finding that overexpression of SHP2 induces motogenesis in insulin-treated cells. These results raised the possibility that the motogenic effect of SHP2 would be uncovered via insulin-mediated suppression of PTP1B and, conversely, that overexpression of PTP1B would block the motogenic effect of SHP2 in insulin-treated cells. As shown in Fig. 9 , overexpression of SHP2 increased cell motility, but only in insulin-treated cells, confirming previous results. Moreover, the effect of insulin on SHP2-induced motogenesis was mimicked, in the absence of insulin, by treatment of cells with dominant negative PTP1B (C215S-PTP1B), an allele that antagonizes PTP1B function. Conversely, overexpression of PTP1B blocked the capacity of insulin to potentiate the mitogenic effect of SHP2 (Fig. 10) .
DISCUSSION
In previous studies, we (11, 13) reported that NO decreases cell motility or proliferation in cultured vascular smooth muscle cells by increasing PTP1B activity via a mechanism mediated by cGMP. Subsequently, we (38) reported that in insulin-treated differentiated aortic smooth muscle cells, NO increases cell motility via the suppression of PTP1B levels and activity.
Numerous studies (31, 35, 36) have reported that ANG II plays an important role in inducing cell motility and that it contributes to vascular remodeling. In the present study, we report the finding that the motogenic effect of NO in insulintreated cells is mediated via a mechanism involving ANG II, thus uncovering a novel pathway of vascular cell activation. The effect of ANG II is mediated via AT 1 R, but not AT 2 R, similar to numerous studies that have reported an effect via AT 1 R. It is also interesting to note that NO alone induced a modest but significant increase of ANG II levels, whereas combined treatment with insulin and NO induced a robust threefold increase of ANG II levels in the culture media. Treatment of cells with ANG II alone induced no significant increase of motility; however, in cells treated with DETA-NO, ANG II increased motility in a concentration-dependent manner, mimicking the comotogenic effect of insulin. Thus, increased ANG II levels are both necessary and sufficient to uncover the motogenic effect of NO.
We (6, 13) have previously reported that both PDGF and NO have the capacity to induce upregulation of the levels and/or activity of PTP1B. Moreover, we found that the capacity of NO to increase PTP1B activity is mediated via a cGMP-dependent mechanism. We (23, 38) have also reported that the comotogenic effect of insulin and PDGF is mediated via the suppression of PTP1B levels as well as PTP1B activity by insulin. This prompted us to test the hypothesis that insulin would similarly suppress the levels and/or activity of PTP1B in NO-treated cells. NO treatment alone failed to change PTP1B protein levels, whereas insulin alone decreased basal PTP1B protein levels. Furthermore, treatment with insulin abrogated the capacity of NO to increase PTP1B activity. If ANG II were involved as a mediator of the comotogenic effect of NO via AT 1 R, we would expect the AT 1 R antagonist losartan to reverse the effect of insulin on PTP1B activity. Indeed, losartan reversed the effect of insulin, consistent with the hypothesis that the suppression of PTP1B activity by insulin is mediated via a novel mechanism involving ANG II.
Studies (9, 15, 37) have identified PI3K as an important mediator of vascular smooth muscle cell activation induced by insulin or ANG II. Moreover, our previous studies (8, 38) identified a requirement for PI3K in NO-induced motogenesis in insulin-treated cells. We (38) also showed that chronic insulin treatment specifically induces an upregulation of the PI3K ␦-isoform in cultured cells, similar to findings in vivo (15) . In the present study, we tested the hypothesis that PI3K-␦ function was both sufficient and necessary to mediate the comotogenic effect of insulin and NO. Indeed, ANG II increased PI3K-␦ levels, confirming previous results. Moreover, suppression of PI3K-␦ levels via siRNA treatment blocked the comotogenic capacity of insulin and NO. Conversely, overexpression of PI3K-␦ uncovered the motogenic capacity of NO. Taken together, these findings indicate that PI3K-␦ function is both sufficient and necessary for transduction of the comotogenic effect of NO.
Previous studies (1, 2) from our laboratory indicated that the comotogenic effect of NO and insulin is mediated via cGMP. Moreover, we (8) reported that NO induces an upregulation of SHP2 via a cGMP-mediated mechanism and that upregulation of SHP2 is both necessary and sufficient to mediate the motogenic effect of NO. In the present study, we uncovered additional novel details on this mechanism, indicating that the suppression of PTP1B mediates the effect of SHP2-induced motogenesis and, conversely, that the upregulation of PTP1B blocks the motogenic effect of SHP2. The mechanism by which the interaction between PTP1B and SHP2 occurs is currently unknown, but we believe that this aspect would be a fruitful area of investigation.
It is interesting to note that in several models that are likely to be associated with hyperinsulinemia, NO has been reported to enhance atherosclerosis rather than protect against it (7, 17, 22, 30) . It is therefore tempting to speculate that the mechanisms outlined in the present investigation may play a role in hyperinsulinemic states in vivo by reducing or even reversing the protective effect of NO in vascular remodeling. Also of note, studies (18, 32) of the effects of NO in patients undergoing angioplasty found no significant decrease of neointimal expansion, perhaps related to the concomitantly high levels of insulin expected to occur in this cohort and the cell signaling pathways outlined in the present report.
In summary, we found that the motogenic effect of NO in insulin-treated differentiated aortic smooth muscle cells requires the function of ANG II and PI3K-␦, followed by the suppression of PTP1B activity. Suppression of PTP1B activity then potentiates the motility stimulatory effect of SHP2, mediating the motogenic effect of NO in insulin-treated cells (Fig. 11) . Investigation of the relevance of our results to vascular remodeling remains to be implemented, but such investigation now appears to be warranted.
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